Please assess the completion status of the following clinical trial:

Trial Title: Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematological neoplasms or solid tumors candidable to high-dose chemotherapy with autologous peripheral stem cell reinfusion~* Adequate organ function~* Written informed consent.~Exclusion Criteria:~* Use of other experimental drugs~* Active infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Filgrastim (Type: ACTIVE_COMPARATOR): Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
- Pegfilgrastim (Type: EXPERIMENTAL): Pegfilgrastim administered the day after autologous stem-cell reinfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).